Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages - Wikidata - awgldk - TriplyDB

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages

http://www.wikidata.org/entity/Q35606537

about

Immunotherapy as treatment for Alzheimer’s disease Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice Immunotherapeutic approaches for Alzheimer's disease Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.White matter changes in dementia: role of impaired drainage of interstitial fluid.Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.Amyloid-beta immunotherapy for Alzheimer's disease Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta.Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.Novel immunological approaches for the treatment of Alzheimer's disease.Immunomodulation for prion and prion-related diseases.Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice.Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model Specific amyloid β clearance by a catalytic antibody construct.Could immunomodulation be used to prevent prion diseases?Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo Therapeutic approaches for prion and Alzheimer's diseases.Anti-dementia drugs and hippocampal-dependent memory in rodents.Novel strategies for Alzheimer's disease treatment.Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.Amyloid-beta immunisation for Alzheimer's disease Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders AD vaccines: conclusions and future directions.Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Murine models of Alzheimer's disease and their use in developing immunotherapies.Antibody-based therapy in Alzheimer's disease.The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.

P2860

Q22241491-1A2494FD-70D3-4B41-AB61-9F55144024AD Q27329865-6C9F93BC-7A3A-4BB2-B6C4-7D9C8B73DD2B Q28081278-4A9DF351-788C-4F90-A846-9F5508D165AA Q30805841-B91EBFAE-84E4-4A6E-BE0F-9D74B0A57397 Q30855109-CA454E27-02FF-4AC7-8F6B-7612FEE8B24A Q30880445-48345E02-5E80-49AA-81D6-31F0E1372D33 Q33718694-6C9EE0A2-7F81-490C-8B75-0766078D2A80 Q33725397-427D87CF-E98F-448A-B44F-E8183798BEA1 Q33742312-0292C4D9-223D-4C92-AC5B-518D84B9B48C Q33771800-12A4B16D-3EA1-447D-A83C-B60FB29CAA89 Q33935251-032DF7F6-43FB-4E5E-92CA-A2F6CBE1A02B Q33954737-5F50B555-E274-4245-8102-8510E9F9A58D Q34020477-0C996ECB-41E8-47C0-A590-3FD70A3A14C3 Q34227162-F32E184E-1743-40BC-A415-E0C9B6EAE565 Q34562675-06FDFF47-3406-41E2-8BEC-DE4FB0F44CAF Q34565644-59D70F84-E865-46CA-B817-9BC2776C9E7C Q34943311-88D69061-F686-43E6-AF84-4B2125D7A6E4 Q35095392-F48C5CCB-4E31-47B7-AA8E-10FAAC72FB47 Q35104249-882437C8-8808-4B68-861C-0975EE8EAB55 Q35451085-2ED207B0-23A8-47EB-B404-8D9CEA24177D Q35875915-AAF00707-7DF0-4936-8A63-125C2B67348F Q36005623-95DA7D21-376A-4685-99D8-96AE45C36903 Q36191001-5FFC72C3-F767-49ED-8378-C772B8D2F018 Q36271462-3AA7666D-E089-4D84-A19B-B616FB342AEE Q36872884-EE1E3D29-B073-4F02-8186-BACA2DAA0CA6 Q36925129-DA435580-DBF5-4EBD-9CF2-BDD85D2575F3 Q37012066-F7C65206-6454-463A-9679-82F9A53B03F9 Q37041524-FDB5E382-1CAF-4FCD-A6CE-FA76370DF138 Q37230661-99888F61-A63A-4CC7-874E-986A63E56596 Q37267918-A50CC18A-1B78-40A9-8C90-7DBD0CD38A42 Q37308949-6E4C5C1A-72F0-43B4-9B65-0C1FD51B2F27 Q37383937-4EC19C88-3BB6-49E2-A1BA-3D3096159A6E Q37438273-D0A816D3-4A83-474B-9958-16812D243AB9 Q37630548-EB1424CB-EF70-47FD-8AB3-D3D476EBDAE5 Q37655247-7CDAD9FB-2DEF-4130-98F0-CEBB6A6A9A90 Q37681432-043196C7-0D14-44AD-84C6-54D081427EA4 Q37685285-5010C9A4-209A-49CF-86D6-3B0C13D153D0 Q37752915-38EC58CD-D58F-48D7-921A-EFDBAB8B6327 Q37831912-949D0655-2E1C-4FD5-A483-C2C05BA34FE7 Q37896029-6E072DCA-05ED-4331-B69D-0C6761EF8AAB

P2860

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages

http://www.wikidata.org/entity/Q35606537

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@ast

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@en

type

label

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@ast

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@en

prefLabel

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@ast

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@en

P1433

Q35606537-52643629-39D1-49DF-A995-842A78093CFF

P1476

Q35606537-6B2E8190-776F-48FE-A89E-76D9CC9A8DB0

P2093

Q35606537-0EE4376F-C218-49EB-8C59-477017E4BD11

Q35606537-1CBC6E55-E27C-4C2B-B809-9EEE75C83B7B

Q35606537-3AA2716F-A042-431E-A0ED-85B72CC56AD0

Q35606537-9DCDF950-2264-4FC6-A932-F7E89BD27C72

Q35606537-CEA2D0AE-18C4-4B15-A9DA-8B686A5FF291

Q35606537-D4681013-1C69-43BE-B7BC-8DB659635AD7

Q35606537-FED71A94-6273-4DAB-9882-9DEEB4E582A2

P2860

Q35606537-014122C4-43CA-49DC-AFC5-6789E077694F

Q35606537-0B732CC0-6F47-4DAC-A20A-32F55E611D3E

Q35606537-1639629E-88FD-4B0B-B623-50041ED2D1B3

Q35606537-204DA8E6-2082-4671-973E-F00453A6FE56

Q35606537-21850727-3B80-4CEA-9D6A-B4EC95E6CC5F

Q35606537-25070D83-9E15-4E32-8292-3FA45A2C4D1E

Q35606537-2A9B7D09-3A88-4EA8-B676-4B3B96AFBBD3

Q35606537-2D9AADD0-6DB0-46E3-8163-37B047F10C97

Q35606537-3899AE25-E6FC-4D57-9C84-F67650AB2143

Q35606537-39E78DA7-000A-4153-8880-CBE30F6361B4

P304

Q35606537-E7CBB883-9D14-4E26-BEE5-044F7C33397B

P31

Q35606537-077FA691-EB85-4C76-84AB-0F63D391377C

P356

Q35606537-F80918E0-B82E-43DC-8133-364EB0C11B95

P407

Q35606537-9F9FE1FF-9484-4CAC-A53E-0FDD64D3ABA7

P433

Q35606537-DE2347FE-54D5-4883-A10C-14EFD7B30149

P478

Q35606537-8C8F3FB4-555E-4418-A7EA-41C9ECC9B7D8

P50

Q35606537-50352B41-2E51-4154-9F0A-5D7A98299B2E

Q35606537-AB45ABBF-B181-4C1A-81F4-E10D2628EE2C

P577

Q35606537-2E730884-4C6B-4668-8BFB-CF2F195CAF56

P5875

Q35606537-FF7F2B5D-AEB1-4EEC-849B-99DF87B001B1

P698

Q35606537-6E90D627-3CCB-49DD-99D6-CC5743727825

P921

Q35606537-065FD05D-69A6-4CFE-A9E5-086F9053BC02

P932

Q35606537-1260F28D-7501-4766-8083-E1C46FD91161

P356

J.1460-9568.2006.05149.X

P1433

European Journal of Neuroscience

P1476

Vaccination of Alzheimer's mod ...... urden without microhemorrhages

@en

P2093

Allal Boutajangout

http://www.w3.org/2001/XMLSchema#string

Ayodeji A Asuni

http://www.w3.org/2001/XMLSchema#string

Blas Frangione

http://www.w3.org/2001/XMLSchema#string

David Quartermain

http://www.w3.org/2001/XMLSchema#string

Elin Knudsen

http://www.w3.org/2001/XMLSchema#string

Henrieta Scholtzova

http://www.w3.org/2001/XMLSchema#string

Yong Sheng Li

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias.

Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.

P304

2530-2542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1460-9568.2006.05149.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Einar M Sigurdsson

Thomas Wisniewski

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6696447

http://www.w3.org/2001/XMLSchema#string

P698

17100841

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1779823

http://www.w3.org/2001/XMLSchema#string